As such, assays of immunity to combat adhesion are in their infancy yet may be of crucial functional importance. == More tractable correlates of immunity == Finding a simpler, more reproducible method of detecting protective anti-Strep A antibodies would accelerate vaccine development. to identifying immune correlates to inform vaccine development. This perspective summarises the findings from natural contamination studies, existing assays of immunity to Strep A, and highlights the gaps in knowledge to guide the development of Strep A vaccines and associated correlates of protection. Subject terms:Translational research, Bacterial infection == Introduction == Group A Streptococcus (Strep A,S. pyogenes) is among the top 10 10 leading causes of global infection-related morbidity and mortality across a diverse clinical spectrum including acute infections such as pharyngitis and impetigo, invasive infections and immune-mediated sequelae including acute rheumatic fever, rheumatic heart disease (RHD) and acute glomerular nephritis1,2. Despite successful treatment with penicillin, Strep A disease control remains challenging, leaving a vaccine as the most effective option for disease prevention3. To date, no licensed vaccine against Strep A exists and there is a lack of understanding of the mechanisms of protective immunity. This is a significant impediment to vaccine development both in terms of identifying optimal antigenic targets of vaccination, and developing assays that act as correlates of protection (CoP), the latter being a major focus of current Strep A research4. Importantly, once identified, CoP assays could replace the need for clinical endpoints in vaccine efficacy trials, reducing the requirement for lengthy and costly studies with the disease as an endpoint5,6. For Strep A, this could obviate the burden of quantifying Strep A pharyngitis in hard-to-reach populations and reduce the need to judge vaccine efficacy based on the incidence of RHD, an autoimmune sequela that may arise years after repeated Strep A infections. CoP assays that are readily transferable between laboratories and countries and Col4a5 use standardized reagents that do not require SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 specialist culture conditions or know-how are more SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 likely SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 to be accepted by licensing authorities. Furthermore, such assays may also allow for ongoing surveillance of immunity in target populations. At present, there are several knowledge gaps hindering the development of such assays for Strep A7, but the gaps are closing. == Natural immunity against Strep A == The strongest evidence of protective immune responses SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 against Strep A is the observed decreased susceptibility to contamination with increasing age7. The frequency of acute Strep A infections peaks in childhood, with a much lower incidence of these diseases in adulthood. By contrast, invasive infections are seen in both the very young and very old populations8. This evidence provides a rationale to believe that an effective vaccine against Strep A is usually achievable. The incidence of symptomatic throat infections, including scarlet fever, increases significantly around 4 years of age9. This could be due to the growth of tonsil tissue allowing greater access for Strep A, increased exposure to other children at the start of school, or simply an artefact of school-aged children being able to articulate throat pain. Towards the end of childhood, the frequency of strep sore throats diminishes markedly. A similar peak and fall in incidence occur with Strep A SDZ 220-581 hydrochloride, SDZ220-581, SDZ-220-581 skin infections, at a slightly earlier age than throat infections7. Invasive infections, seen in both the very young and very old populations10, may be associated with immune system naivety and immunosenescence respectively, along with the increased risk of skin injury and uncovered portals of entry. == Immunity to primary infection == Non-invasive infections would be the ideal target of vaccination. The mechanisms that confer resistance to colonisation and primary contamination of the oropharynx or skin are unknown, but likely include a combination of prevention of bacterial adhesion, innate defence mechanisms, opsonophagocytic killing of bacteria supported by antibody and complement, inhibition of directly acting virulence factors, inhibition of bacterial immune evasion strategies, and cellular immunity. During streptococcal infections, there appears to be a temporal sequence of adherence and colonisation by the bacteria. The initial pioneer cells perform long-range adherence and form molecular bridges with host proteins11. The following settler cells have shorter-range adherence with higher affinity and specificity. As the bacterial society forms in biofilms, there is environmental sensing, extracellular polymeric material formation and quorum sensing. Finally, a community is established with cell-to-cell signalling, coaggregation, metabolic synergy and genetic exchange11. It is unknown against which stage or stages of colonisation an effective immune response must act to inhibit the development of contamination, or whether targeting one or more stages by.